Literature DB >> 22960106

Defects in neuromuscular junction remodelling in the Smn(2B/-) mouse model of spinal muscular atrophy.

Lyndsay M Murray1, Ariane Beauvais1, Kunal Bhanot1, Rashmi Kothary2.   

Abstract

Spinal muscular atrophy (SMA) is a devastating childhood motor neuron disease caused by mutations and deletions within the survival motor neuron 1 (SMN1) gene. Although other tissues may be involved, motor neurons remain primary pathological targets, with loss of neuromuscular junctions (NMJs) representing an early and significant event in pathogenesis. Although defects in axonal outgrowth and pathfinding have been observed in cell culture and in lower organisms upon Smn depletion, developmental defects in mouse models have been less obvious. Here, we have employed the Smn(2B/-) mouse model to investigate NMJ remodelling during SMA pathology, induced reinnervation, and paralysis. We show that whilst NMJs are capable of remodelling during pathogenesis, there is a marked reduction in paralysis-induced remodelling and in the nerve-directed re-organisation of acetylcholine receptors. This reduction in remodelling potential could not be attributed to a decreased rate of axonal growth. Finally, we have identified a loss of terminal Schwann cells which could contribute to the defects in remodelling/maintenance observed. Our work demonstrates that there are specific defects in NMJ remodelling in an intermediate SMA mouse model, which could contribute to or underlie pathogenesis in SMA. The development of strategies that can promote the remodelling potential of NMJs may therefore be of significant benefit to SMA patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endplate; Neuromuscular junction; Remodelling; Schwann cell; Spinal muscular atrophy; Sprouting

Mesh:

Substances:

Year:  2012        PMID: 22960106     DOI: 10.1016/j.nbd.2012.08.019

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  37 in total

1.  AAV9-Stathmin1 gene delivery improves disease phenotype in an intermediate mouse model of spinal muscular atrophy.

Authors:  E Villalón; R A Kline; C E Smith; Z C Lorson; E Y Osman; S O'Day; L M Murray; C L Lorson
Journal:  Hum Mol Genet       Date:  2019-11-15       Impact factor: 6.150

2.  Selective vulnerability in neuronal populations in nmd/SMARD1 mice.

Authors:  Eric Villalón; Monir Shababi; Rachel Kline; Zachary C Lorson; Kyra M Florea; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2018-02-15       Impact factor: 6.150

3.  Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy.

Authors:  Laurent P Bogdanik; Melissa A Osborne; Crystal Davis; Whitney P Martin; Andrew Austin; Frank Rigo; C Frank Bennett; Cathleen M Lutz
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

Review 4.  Clinical relevance of terminal Schwann cells: An overlooked component of the neuromuscular junction.

Authors:  Katherine B Santosa; Alexandra M Keane; Albina Jablonka-Shariff; Bianca Vannucci; Alison K Snyder-Warwick
Journal:  J Neurosci Res       Date:  2018-03-13       Impact factor: 4.164

5.  Temporal requirement for SMN in motoneuron development.

Authors:  Le T Hao; Phan Q Duy; James D Jontes; Marc Wolman; Michael Granato; Christine E Beattie
Journal:  Hum Mol Genet       Date:  2013-03-03       Impact factor: 6.150

6.  Chronic Pharmacological Increase of Neuronal Activity Improves Sensory-Motor Dysfunction in Spinal Muscular Atrophy Mice.

Authors:  Christian M Simon; Beatriz Blanco-Redondo; Jannik M Buettner; John G Pagiazitis; Emily V Fletcher; Josiane K Sime Longang; George Z Mentis
Journal:  J Neurosci       Date:  2020-11-20       Impact factor: 6.167

7.  Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation.

Authors:  Shingo Kariya; Teresa Obis; Caterina Garone; Turgay Akay; Fusako Sera; Shinichi Iwata; Shunichi Homma; Umrao R Monani
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

8.  Neurotransmitter release in motor nerve terminals of a mouse model of mild spinal muscular atrophy.

Authors:  Rocío Ruiz; Lucía Tabares
Journal:  J Anat       Date:  2013-03-13       Impact factor: 2.610

Review 9.  Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy.

Authors:  Omar Sheikh; Toshifumi Yokota
Journal:  BioDrugs       Date:  2021-06-07       Impact factor: 5.807

Review 10.  Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?

Authors:  Monir Shababi; Christian L Lorson; Sabine S Rudnik-Schöneborn
Journal:  J Anat       Date:  2013-07-22       Impact factor: 2.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.